GlassScriptPhysician profile
Jon A Peacock
NPI 1275507071
$2,884.84
in general payments reported to CMS, 2019-2025
24 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $117 · 2021: $450 · 2022: $770 · 2023: $439 · 2024: $217 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $478.73 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $457.63 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $219.01 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $213.33 | 2019-2025 | Camzyos, Eliquis, Sotyktu |
| Merck Sharp & Dohme LLC | $193.73 | 2021-2023 | Verquvo |
| Pfizer INC. | $153.52 | 2019-2024 | |
| Stryker Corporation | $148.42 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $141.08 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $140.72 | 2022 | |
| Abbott Laboratories | $132.62 | 2021-2022 | |
| Amgen INC. | $112.46 | 2019 | |
| Astellas Pharma US INC | $83.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.49 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $56.45 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $44.33 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.02 | 2024-2025 | Watchman Flx, Bodyguardian |
| Sanofi-Aventis U.S. LLC | $35.76 | 2019-2024 | |
| Amarin Pharma, INC. | $32.95 | 2021 | |
| Irhythm Technologies, INC. | $31.67 | 2020 | |
| Esperion Therapeutics, INC. | $26.97 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.63 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $23.50 | 2019 | |
| Itamar Medical INC | $19.81 | 2025 | Watchpatone |
| Alnylam Pharmaceuticals INC. | $17.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Peacock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.